The association between glaucoma and all-cause mortality in middle-aged and elderly Chinese people: results from the China Health and Retirement Longitudinal Study

Xiaoxu Huang; Mengqiao Xu; Minwen Zhou; Wenjia Liu; Xiaohuan Zhao; Xiaodong Sun

doi:10.4178/epih.e2023066

Articles

Page Path: HOME > Epidemiol Health > Volume 45; 2023 > Article

Original Article The association between glaucoma and all-cause mortality in middle-aged and elderly Chinese people: results from the China Health and Retirement Longitudinal Study: Xiaoxu Huang^1,2,3*, Mengqiao Xu^1,2,3*, Minwen Zhou^1,2,3, Wenjia Liu^1,2,3, Xiaohuan Zhao^1,2,3, Xiaodong Sun^1,2,3; Epidemiol Health 2023;45:e2023066.
DOI: https://doi.org/10.4178/epih.e2023066
Published online: July 21, 2023

¹Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China

²National Clinical Research Center for Eye Disease, Shanghai, China

³Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China

Correspondence: Xiaodong Sun Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Hongkou District, Shanghai, China E-mail: zhaoxiaohuanleslie@163.com

Co-correspondence: Xiaohuan Zhao Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Hongkou District, Shanghai, China E-mail: xdsun@sjtu.edu.cn

*Huang & Xu contributed equally to this work as joint first authors.

• Received: January 25, 2023 • Accepted: July 4, 2023

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,383 Views
96 Download

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
SUPPLEMENTARY MATERIALS
NOTES
ACKNOWLEDGEMENTS
REFERENCES

Abstract

OBJECTIVES
This population-based, prospective cohort study investigated the association between glaucoma and mortality in older adults.
METHODS
Participants aged 45 years or older at baseline (47.9% male) were enrolled in 2011 for the China Health and Retirement Longitudinal Study (CHARLS). All-cause mortality was observed during 7 years of follow-up. The baseline data were collected in the 2011 CHARLS, and participants were followed up for 7 years (until 2018). The risk of all-cause mortality was investigated using Cox proportional-hazards regression with age as the time scale, adjusting for significant risk factors and comorbid conditions.
RESULTS
Among the 14,803 participants included, the risk of all-cause death was significantly higher among people with glaucoma than among those without glaucoma, after adjustment for other confounders (hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.04 to 2.03). In a subgroup analysis based on the mean age of death, among those who were 75 years and older (n=1,231), the risk of all-cause death was significantly higher in patients with glaucoma than in those without glaucoma (HR, 1.89; 95% CI, 1.24 to 1.89).
CONCLUSIONS
Participants with glaucoma had a higher risk of all-cause mortality, especially those aged 75 years and above. Our findings revealed potential mechanisms underlying an association between glaucoma and all-cause mortality. They also highlighted the importance of glaucoma management to prevent premature death in middle-aged and older adults.
Keywords: Glaucoma, Mortality, China Health and Retirement Longitudinal Study, Risk factors

INTRODUCTION

Glaucoma is a chronic, progressive disease characterised by structural changes to the optic nerve head and visual field loss [1]. Worldwide, the number of glaucoma patients has increased rapidly in recent decades, and it is expected to reach 112 million by 2040 [2]. In China, 13.12 million patients had glaucoma in 2015, accounting for 2.58% of the total population. The prevalence is estimated to increase to 3.48% by 2050, when 25.16 million people will be diagnosed with glaucoma in China [3]. Glaucoma has an uncertain prognosis and requires lifelong management and follow-up to prevent further loss of vision [4]. Therefore, it poses a major public health challenge with considerable social and economic impacts in China, which has one of the highest totals of glaucoma cases worldwide [5,6]. As the most frequent cause of blindness [7,8], glaucoma has a serious impact on life expectancy, especially for the elderly. A possible association between glaucoma and mortality has been noted since 1950 [9].

The relationship between glaucoma and mortality varies significantly in different studies. The Beijing Eye Study, using a multivariate model, observed a higher mortality rate in angle-closure glaucoma patients [10]. Furthermore, studies analysing Taiwanese health insurance data and an Indian rural cohort reported that primary open-angle glaucoma (POAG) was associated with higher 10-year mortality [11,12]. However, a meta-analysis of 9 studies presented no convincing evidence for a higher risk of all-cause mortality among those with POAG [13]. Similarly, there was no evidence of an association between POAG and survival in a Scandinavian cohort that was followed for up to 30 years [14]. Interestingly, in the population-based National Health and Nutrition Examination Survey (NHANES), a representative health survey conducted in the United States, glaucoma was related to a higher incidence of mortality in an unadjusted Cox regression model, but the correlation disappeared when the model was adjusted for age and sex [15].

In view of the anticipated increase in the incidence of glaucoma worldwide and the uncertainty of the evidence concerning the associated risk of death, there is a need for further research into the life expectancy of glaucoma patients [13,16]. Therefore, our research evaluated the relationship between glaucoma and mortality through the population-based China Health and Retirement Longitudinal Study (CHARLS). We investigated whether glaucoma is associated with increased mortality in subjects affected by comorbidities (such as diabetes or hypertension) and considered other potentially confounding factors.

Study population and design: The CHARLS is a nationally representative longitudinal survey of middle-aged and elderly Chinese people (45 years and older). The national public database covers a wide range of information concerning family, health status and function, health care and insurance, work, retirement and pension, and physical measurements. A multistage probability sampling method was applied through the CHARLS, which covered 28 provinces, 150 counties and districts, and 450 villages or urban communities across China. A total of 17,705 individuals were recruited between June 2011 and March 2012 [17]. All participants underwent face-toface, computer-assisted personal interviews, which included a structured questionnaire, and follow-up occurred every 2 years. Physical measurements, including height, weight, and blood pressure, were evaluated at each follow-up, and blood samples were collected once in every 2 follow-up cycles. CHARLS has been described in more detail elsewhere [18].
Assessment of glaucoma: Glaucoma was assessed via self-reports both at baseline and during follow-up. The presence of glaucoma was defined by a selfreported answer to the question, “Has a doctor, nurse, or paramedical ever treated you for glaucoma?” If the respondent answered “yes” to this question, the conclusion was that they had glaucoma. Participants with a pre-existing glaucoma diagnosis at baseline were excluded from the present study, and the enrolled participants received follow-up glaucoma assessments in 2013, 2015, and 2018. The range of glaucoma considered includes all types: POAG, primary angle-closure glaucoma, and secondary glaucoma.
Follow-up of all-cause mortality: Participants enrolled in wave 1 (2011, baseline) were followed up in waves 2, 3, and 4 (2013, 2015, and 2018). Interview status (dead or alive) and date of death were recorded in wave 4. For those who had died from any cause, the survival time was calculated as the interval between baseline and the date of death. If the exact date of death was not available, the survival time was defined as the median of the interval between the baseline time and the specific wave in which information about the death was received. For those who had not died during the follow-up period, their survival time was considered to be the interval between 2 interview waves.
Confounding variables: Information that included age, sex, educational level (primary or below, middle school, high school, or college and above), marital status (married or partnered, or otherwise), smoking (yes or no), and drinking (drinking more than once a month, drinking less than once a month, or none) was collected by trained interviewers using the 2011 CHARLS questionnaire. Respondents were categorised into different groups. Body mass index (BMI) was used to describe the obesity status of respondents and was defined as one’s body mass divided by the square of their height in units of kg/m2. Hypertension was defined as blood pressure ≥ 140/90 mmHg at baseline or a self-reported history of antihypertensive medication use. Dyslipidaemia was defined by having a self-reported dyslipidaemia history or as having more than one of the following: total cholesterol ≥ 6.2 mmol/L, low-density lipoprotein cholesterol ≥ 4.1 mmol/L, triglycerides ≥ 2.3 mmol/L, or high-density lipoprotein cholesterol < 1.0 mmol/L. Diabetes was defined as a selfreported diagnosis of diabetes, as a fasting plasma glucose level ≥ 7.0 mmol/L, or as glycated haemoglobin 6.5% [19].
Serum measurements: Trained nurses collected 8 mL of fasting blood samples at township health centres or at the local offices of the Chinese Centre for Disease Control and Prevention (CDC) after participants had fasted for at least eight hours overnight. The whole blood and centrifugal serum were transported to the CDC at -20°C and stored at -80°C. Levels of plasma glucose, lipids, and glycosylated haemoglobin were then measured in a laboratory at Capital Medical University.
Statistical analysis: Continuous data were expressed as mean± standard deviation and analysed using the Student t-test for group comparisons, whereas categorical data were presented as numbers (n) with percentages (%) and analysed using the chi-square test for group comparisons. The overall significance of the univariate survival analysis was determined by the log-rank test using the Kaplan-Meier analysis. Cox proportional-hazards regression analyses were carried out according to glaucoma status to obtain hazard ratios (HR) and 95% confidence intervals (CIs) for risk factors significantly associated with mortality. The proportional-hazard assumption was tested based on Schoenfeld residuals and the Kaplan-Meier survival curve, and no violation was found. The Cox proportional-hazards regression model was adjusted for potentially confounding factors. A subgroup analysis was conducted based on the average age at death, and participants were divided into 2 subgroups: those aged 45-74 years and those 75 years and older. All statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), and a 2-sided p-value < 0.05 was considered statistically significant.
Ethics statement: CHARLS was approved by the Ethical Review Committee at Peking University.

RESULTS

In total, 14,803 participants were included for analysis after filtering (Figure 1). Table 1 shows the baseline characteristics of the participants in our study. Of the 14,803 participants meeting the criteria for enrolment, 141 (0.9%) were diagnosed with glaucoma. Compared to the participants with glaucoma, those without glaucoma were younger (66.6 ± 10.1 vs. 59.0 ± 9.9, p < 0.001), were more likely to be male, educated, and married or partnered; to smoke; and to consume alcohol; and less likely to have hypertension, dyslipidaemia, or diabetes.

Figure 2 presents the survival probability of the groups with and without glaucoma by Kaplan-Meier analysis. In general, across all age-based strata, the survival probability of individuals diagnosed with glaucoma was significantly lower than that of the non-glaucoma group (p< 0.001, Figure 2A). We further stratified patients by average age of death and found that survival probability was significantly associated with glaucoma status in people aged 75 years and older (p= 0.002, Figure 2C), but not in people aged 45-74 years (p= 0.102, Figure 2B).

During the 7-year follow-up, there were 1,627 deaths among all participants. At baseline, the participants who died with glaucoma were significantly older than those who died without glaucoma (75.94 vs. 68.99 years, p< 0.001), were less likely to be male (38.9 vs. 58.9%, p= 0.016), and were less likely to smoke (30.6 vs. 51.0%, p= 0.015) (Supplementary Material 1). Considering the strong association between age and death over time, we further stratified by age according to average age at death to explore whether glaucoma status was associated with all-cause mortality. The characteristics of patients who died according to glaucoma status, stratified by age group, are shown in Supplementary Material 2. Among individuals between 45 years and 74 years at time of death, the age distribution differed between the glaucoma and non-glaucoma groups.

Risk factors associated with all-cause mortality are presented in Tables 2 and 3. The multivariate Cox regression analysis indicated that individuals with glaucoma had a higher risk of all-cause mortality than those without glaucoma (HR, 1.46; 95% CI, 1.04 to 2.03), even if adjusting for age, sex, and comorbid conditions. In addition, lifestyle factors, such as smoking and drinking, and chronic systemic diseases, including hypertension and diabetes, increased the risk of all-cause mortality. Subjects with a low educational level also had a higher risk of all-cause mortality. Being married or living with a partner correlated to a lower risk of allcause mortality. In the Cox proportional-hazards regression analysis, elevated BMI was not associated with excess all-cause mortality risk. A higher BMI was even found to be a protective factor, with statistical significance (HR, 0.92; 95% CI, 0.91 to 0.94).

After being stratified by age, individuals 75 years and older with glaucoma still showed a higher risk of all-cause mortality after age and concomitant conditions were considered (HR, 1.89; 95% CI, 1.24 to 2.89; Table 3). The predictive factors for mortality among such individuals included having less education, never having married or had a partner, smoking, and having hypertension. In the younger group, the factors predictive of mortality included being male, having less education, never having married or had a partner, smoking, drinking, having hypertension, and having diabetes.

DISCUSSION

Overall, our current results based on a set of representative Chinese people strongly suggest that glaucoma is a high-risk factor for all-cause mortality in the middle-aged and elderly population, especially among people older than 75 years. In our study, among participants of all ages, the presence of glaucoma is accompanied by a higher risk of all-cause mortality (HR, 1.46; 95% CI, 1.04 to 2.03), even after considering other conditions that might affect the risk of mortality, such as age, sex, BMI, smoking, drinking, hypertension, dyslipidaemia, and diabetes. When stratified by mean age of death, glaucoma significantly increases all-cause mortality in individuals in their mid-70s and older (HR, 1.89; 95% CI, 1.24 to 2.89). However, among younger individuals of 45 years to 74 years of age, those with glaucoma are not at higher risk compared with their same-age peers.

The results of our study agree with many previous findings [10,11,20-25]. The National Health Interview Survey (NHIS) [25] reported that the probability of death from any cause occurring over a median of 7 years of follow-up was higher (HR, 1.35; 95% CI, 1.19 to 1.53) among participants with glaucoma compared to those without glaucoma, even after adjustment for confounders. The NHIS survey also reported a higher risk of mortality from cardiovascular disease among participants with glaucoma. Similarly, a Taiwanese study [11] demonstrated higher mortality associated with POAG (adjusted HR, 2.11; 95% CI, 1.76 to 2.54), and it observed an association between glaucoma and a higher risk of acute renal failure. Moreover, the Beijing study, which examined 4,356 subjects for glaucoma, suggested that glaucoma, especially angle-closure glaucoma, might be associated with an increased rate of mortality among Chinese adults in Greater Beijing [10]. Previous studies on the relationship between glaucoma and all-cause mortality were mainly conducted in developed countries, such as Australia, the United States, and Sweden [25-27]. In the following decade, relevant studies on all-cause mortality of glaucoma were also carried out in some areas of China. Few studies focused on glaucoma patients in the whole country, however, and most of them were small-scale studies, limited to local sampling in individual provinces and cities, such as studies conducted in Taiwan study [11] and Beijing [10]. The sampling coverage of our study was broader. Due to China’s vast territory and large population, people in different regions also show different characteristics of eye diseases. For example, the incidence of glaucoma in northern China, such as Inner Mongolia and Harbin, is 1.4% and 0.7%, respectively [28,29], while the incidence of glaucoma in Liwan District in southern China is 2.1%. Therefore, our study can better represent the mortality characteristics of the glaucoma population in China. It supports and extends these findings reporting an association between glaucoma and mortality, and it improves the understanding of glaucoma’s impact on the older population across China, one of the countries with the highest number of glaucoma cases [5,6].

In contrast to our study, the NHANES study showed no statistically significant association between glaucoma and mortality after adjusting for age and sex [15]. Several studies have found an association between glaucoma and mortality in univariate analyses, but the association disappeared after adjustment for confounders [12,30]. In general, the relationship between glaucoma and mortality varies considerably across different studies, but this may relate to factors such as race, geography, sampling quantity, and method. These factors may explain the differences in results between those studies and ours.

It is worth noting that our results clarify the association between glaucoma and all-cause mortality in different age groups by showing that, in people 75 years and older, age is an important component of increased all-cause mortality from glaucoma. This may be because aging is one of the main factors that promote the course of glaucoma and affect its treatment [31]. Few earlier studies in Asia have stratified their participants by age. The focus of some studies was the whole set of participants, without age stratification between younger and older groups, such as the study on this topic conducted in Taiwan [11]. Other studies focused on the association between glaucoma and mortality in people over 40 years, such as a rural cohort study from India and the above-mentioned study from Beijing [10,12]. As population aging continues worldwide, glaucoma among elderly people will exacerbate the disease and economic burden in Asia, especially in China. Aging will aggravate the disease’s severity and contribute to an increase in all-cause mortality. Our study is intended to raise more concerns about the survival status of glaucoma patients over the age of 75.

Potential mechanisms that may explain the increased risk of mortality in adults with glaucoma include adverse treatment effects and exposure to risk factors that are known to increase the risk of glaucoma and of major cause-specific deaths. First, adverse treatment effects from glaucoma surgery and medications are reported to be associated with high all-cause mortality rates. A retrospective cohort study from Korea indicated that all-cause mortality due to surgery for glaucoma was statistically significant (adjusted HR, 1.31; 95% CI, 1.05 to 1.62) for both open-angle glaucoma and angle-closure glaucoma [32]. The risk of death from neurological diseases was 2.7 times higher in older patients who underwent glaucoma surgery than in those who only received a diagnosis of glaucoma. Glaucoma medications can also cause severe side effects, including congestive heart failure (topical cholinergic agonists), increased blood pressure, and tachyarrhythmias (topical adrenergic agonists) [33]. The topical administration of a beta-blocker is one of the most common treatments for glaucoma; however, it is associated with increased mortality. Both a 2006 Australian study (relative risk [RR], 2.14; 95% CI, 1.18 to 3.89) and research conducted in the United States in 2008 (RR, 1.91, p = 0.04) showed higher mortality among glaucoma patients treated with topical timolol [26,34]. This could be attributed to the drug’s effect on blood lipid levels, such as a 20% reduction in high-density lipoprotein cholesterol and a 20-40% increase in triglycerides [35]. However, the conclusions were contradictory. A retrospective cohort analysis in the United States indicated that the use of any type of glaucoma medication had a statistically significant association with a 7% reduction in mortality (adjusted HR, 0.93; 95% CI, 0.90 to 0.95) [36]. Another United States study, from the same year, showed similar results (HR, 0.26; 95% CI, 0.16 to 0.40) [33]. The use of topical beta-blockers did not seem to be associated with excess mortality [37]. Second, exposure to risk factors known to increase the risk of both glaucoma and major cause-specific deaths (e.g., neurological disease, cardiovascular disease) may also contribute to high glaucoma-associated levels of mortality. The association between neurological diseases and glaucoma can be interpreted through the mechanisms that cause haemodynamic changes in the cerebral arteries and pathological substances, such as protein tau and amyloid-beta, which cause neurotoxicity and are also strongly associated with optic nerve damage in glaucoma [38]. It has been suggested that stroke [39- 41], Alzheimer’s disease [42-44], and Parkinson’s disease [45-47] are neurological diseases related to glaucoma. There was evidence that mortality in glaucoma patients was closely associated with cardiovascular events. A study in Australia indicated that cardiovascular mortality was 14.6% in patients with glaucoma as compared to 8.4% in non-glaucoma individuals, while further stratified analyses showed that cardiovascular mortality was higher among those previously diagnosed with glaucoma (RR, 1.85; 95% CI, 1.12 to 3.04) [26].

The current study has several strengths. First, it is a large-scale longitudinal study of elderly Chinese people with nationwide representation, a high participation rate, objective quality standards, and access to a complete, adjudicated registry of deaths. Second, the participants were randomly recruited from the general population; therefore, the results may be generalisable to the national elderly population. Last but not least, our study included an agestratified analysis, which enabled focusing on the elderly, especially those aged 75 years and older. This may help in evaluating the survival status of individuals with glaucoma in different age groups and provide a reference for future clinical decision-making.

Several study limitations should also be noted. First, the data on glaucoma were self-reported. Although there are some differences in evaluation between self-reports and clinical data, some studies support the reliability of self-reports for eye diseases including glaucoma [15,48,49]. Second, we did not collect information on the use of antiglaucoma medication, which might have explained the higher risk of mortality. Third, we explored the association between glaucoma and mortality, but did not include specific causes of death due to limited data. Further work could include the collection of medication information and participants’ specific causes of death to improve the accuracy of the analysis.

Despite these limitations, the present study suggests that glaucoma may be associated with a higher rate of mortality in middle-aged and elderly people in China, especially for those aged 75 years and older. This study provides an important reference for the design and evaluation of clinical glaucoma treatment and the management of patients of different ages.

SUPPLEMENTARY MATERIALS

Supplementary materials are available at https://www.e-epih.org/.

Supplementary Material 1.

Baseline characteristics by glaucoma in those who died among all population

epih-45-e2023066-Supplementary-1.docx

Supplementary Material 2

Baseline characteristics by glaucoma in those who died in different age group

epih-45-e2023066-Supplementary-2.docx

NOTES

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare for this study.

FUNDING

This research was supported by the National Natural Science Foundation of China (82171076), Science and Technology Commission of Shanghai Municipality (20Z11900400), Shanghai Hospital Development Center (SHDC2020CR2040B, SHDC2020CR5014), and Shanghai Collaborative Innovation Center for Translational Medicine (TM202115PT).

AUTHOR CONTRIBUTIONS

Conceptualization: Huang X, Zhao X, Sun X. Data curation: Huang X, Xu M. Formal analysis: Zhou M, Liu W. Funding acquisition: Sun X. Methodology: Zhou M. Project administration: Sun X. Visualization: Zhao X, Sun X. Writing – original draft: Huang X, Xu M, Liu W. Writing – review & editing: Zhao X, Sun X, Zhou M.

ACKNOWLEDGEMENTS

None.

Figure 1.

Flow chart of the study sample of middle-aged and older Chinese adults: China Health and Retirement Longitudinal Study, 2011- 2018.

Figure 2.

Data on the survival probability of individuals with glaucoma (A) all ages, (B) aged 45-74 years, and (C) aged 75 years and older. HR, hazard ratio; CI, confidence interval.

Table 1.

Participant characteristics

Characteristics		Glaucoma		p-value
Characteristics		Yes (n=141)	No (n=14,662)	p-value
Age (yr)		66.6±10.1	59.0±9.9	<0.001
Sex				<0.001
	Male	47 (33.3)	7,039 (48.0)
	Female	94 (66.7)	7,623 (52.0)
Body mass index (kg/m²)		23.2±3.3	23.4±3.4	0.495
Education				0.013
	Primary or below	114 (80.9)	9,996 (68.2)
	Middle school	16 (11.3)	3,014 (20.6)
	High school	8 (5.7)	1,069 (7.3)
	College or above	3 (2.1)	583 (4.0)
Marital status				<0.001
	Married or partnered	110 (78.0)	12,869 (87.8)
	Otherwise	31 (22.0)	1,793 (12.2)
Smoking				0.036
	Yes	44 (31.2)	5,849 (39.9)
	No	97 (68.8)	8,813 (60.1)
Drinking				0.031
	None	109 (77.3)	9,801 (66.8)
	Drink but less than once a month	8 (5.7)	1,138 (7.8)
	Drink more than once a month	24 (17.0)	3,723 (25.4)
Hypertension				<0.001
	Yes	52 (36.9)	3,519 (24.0)
	No	89 (63.1)	11,143 (76.0)
Dyslipidaemia				0.003
	Yes	24 (17.0)	1,315 (9.0)
	No	117 (83.0)	13,347 (91.0)
Diabetes				<0.001
	Yes	20 (14.2)	803 (5.5)
	No	121 (85.8)	13,859 (94.5)

Values are presented as mean±standard deviation or number (%).

Table 2.

Cox proportional hazards regression models of all-cause mortality by glaucoma among all participants

Variables		HR (95% CI)	p-value
Glaucoma: Yes vs. no		1.46 (1.04, 2.03)	0.027
Age (yr)		1.09 (1.08, 1.09)	<0.001
Sex: Male vs. female		1.82 (1.59, 2.08)	<0.001
Body mass index (per 1 kg/m²)		0.92 (0.91, 0.94)	<0.001
Education: Primary or below vs. college or above		1.74 (1.28, 2.35)	<0.001
	Middle school vs. college or above	1.69 (1.22, 2.35)	0.002
	High school vs. college or above	1.24 (0.81, 1.89)	0.317
Marital status: Married or partnered vs. other		0.39 (0.35, 0.44)	<0.001
Smoking: Yes vs. no		1.25 (1.09, 1.42)	0.001
Drinking: Drink less than once a month vs. drink more than once a month		0.84 (0.67, 1.07)	0.164
	None vs. drink more than once a month	1.38 (1.22, 1.56)	0.001
Hypertension: Yes vs. no		1.80 (1.62, 2.01)	<0.001
Dyslipidaemia: Yes vs. no		0.88 (0.73, 1.06)	0.320
Diabetes: Yes vs. no		1.70 (1.42, 2.03)	<0.001

HR, hazard ratio; CI, confidence interval.

Table 3.

Cox proportional hazards regression models of all-cause mortality by glaucoma per age group

Variables		Participants aged (yr)
Variables		45-74 (n=13,572)	p-value	≥75 (n=1,231)	p-value
Glaucoma: Yes vs. no		1.39 (0.81, 2.41)	0.235	1.89 (1.24, 2.89)	0.003
Sex: Male vs. female		1.99 (1.67, 2.36)	<0.001	1.21 (0.97, 1.50)	0.088
Body mass index (per 1 kg/m²)		0.93 (0.92, 0.95)	<0.001	0.98 (0.95, 1.00)	0.062
Education: Primary or below vs. college or above		1.69 (1.18, 2.42)	0.004	1.86 (1.04, 3.32)	0.037
	Middle school vs. college or above	1.30 (0.89, 1.89)	0.172	0.73 (0.33, 1.60)	0.432
	High school vs. college or above	0.71 (0.45, 1.13)	0.152	2.14 (0.69, 6.67)	0.188
Marital status: Married or partnered vs. otherwise		0.53 (0.45, 0.62)	<0.001	0.83 (0.69, 0.99)	0.038
Smoking: Yes vs. no		1.34 (1.14, 1.58)	<0.001	1.26 (1.03, 1.55)	0.027
Drinking: Drink less than once a month vs. drink more than once a month		0.76 (0.58, 1.01)	0.055	1.00 (0.63, 1.57)	0.993
	None vs. drink more than once a month	1.34 (1.15, 1.55)	<0.001	1.33 (1.06, 1.68)	0.015
Hypertension: Yes vs. no		1.78 (1.55, 2.04)	<0.001	1.25 (1.04, 1.49)	0.015
Dyslipidaemia: Yes vs. no		0.88 (0.71, 1.09)	0.245	0.95 (0.68, 1.33)	0.784
Diabetes: Yes vs. no		2.03 (1.65, 2.50)	<0.001	1.03 (0.72, 1.49)	0.860

Values are presented as hazard ratio (95% confidence interval).

REFERENCES

1. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet 2017;390:2183-2193.Article PubMed
2. Tham YC, Cheung CY, Wong TY, Baskaran M, Liu J, Lee BH, et al. Validity of a new optic disc grading software for use in clinical and epidemiological research. Clin Exp Ophthalmol 2013;41:842-852.Article PubMed
3. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: a systematic analysis. J Glob Health 2017;7:020705.Article PubMed PMC
4. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311:1901-1911.Article PubMed PMC
5. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol 2001;85:1277-1282.Article PubMed PMC
6. He M, Foster PJ, Johnson GJ, Khaw PT. Angle-closure glaucoma in east Asian and European people. Different diseases? Eye (Lond) 2006;20:3-12.Article PubMed PDF
7. Bourne R, Price H, Taylor H, Leasher J, Keeffe J, Glanville J, et al. New systematic review methodology for visual impairment and blindness for the 2010 global burden of disease study. Ophthalmic Epidemiol 2013;20:33-39.Article PubMed PMC
8. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081-2090.Article PubMed
9. Leske MC. Glaucoma and mortality: a connection? Ophthalmology 2003;110:1473-1475.Article PubMed
10. Xu L, Wang YX, Jonas JB. Glaucoma and mortality in the Beijing Eye Study. Eye (Lond) 2008;22:434-438.Article PubMed PDF
11. Chou CL, Hsieh TC, Chen JS, Fang TC. Risks of all-cause mortality and major kidney events in patients with new-onset primary open-angle glaucoma: a nationwide long-term cohort study in Taiwan. BMJ Open 2018;8:e021270.Article PubMed PMC
12. Khanna RC, Murthy GV, Giridhar P, Marmamula S, Pant HB, Palamaner Subash Shantha G, et al. Glaucoma-associated longterm mortality in a rural cohort from India: the andhra pradesh eye disease study. Br J Ophthalmol 2018;102:1477-1482.Article PubMed
13. Akbari M, Akbari S, Pasquale LR. The association of primary open-angle glaucoma with mortality: a meta-analysis of observational studies. Arch Ophthalmol 2009;127:204-210.Article PubMed
14. Sundqvist J, Ekström C. Open-angle glaucoma and mortality: a long-term follow-up study. Acta Ophthalmol 2018;96:e1038. e1039.Article PDF
15. Kühn T, Rohrmann S, Karavasiloglou N, Friedman DS, Cassidy A, Bärnighausen T, et al. Glaucoma and mortality risk: findings from a prospective population-based study. Sci Rep 2021;11:11771.Article PubMed PMC PDF
16. Pache M, Flammer J. A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol 2006;51:179-212.Article PubMed
17. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol 2014;43:61-68.Article PubMed PMC
18. Zhao X, Zhou Y, Wei K, Bai X, Zhang J, Zhou M, et al. Associations of sensory impairment and cognitive function in middleaged and older Chinese population: the China Health and Retirement Longitudinal Study. J Glob Health 2021;11:08008.Article PubMed PMC
19. Xie D, Wang J. Comparison of self-reports and biomedical measurements on hypertension and diabetes among older adults in China. BMC Public Health 2020;20:1664.Article PubMed PMC PDF
20. Wang L, Zhu Z, Huang W, Scheetz J, He M. Association of glaucoma with 10-year mortality in a population-based longitudinal study in urban Southern China: the Liwan Eye Study. BMJ Open 2021;11:e040795.Article PubMed PMC
21. Xu L, Wang YX, Wang J, Jonas JJ. Mortality and ocular diseases: the Beijing Eye Study. Ophthalmology 2009;116:732-738.Article PubMed
22. Hiller R, Podgor MJ, Sperduto RD, Wilson PW, Chew EY, D’Agostino RB. High intraocular pressure and survival: the framingham studies. Am J Ophthalmol 1999;128:440-445.Article PubMed
23. Egge K, Zahl PH. Survival of glaucoma patients. Acta Ophthalmol Scand 1999;77:397-401.Article PubMed PDF
24. Thorburn W, Lindblom B. Survival time among patients with glaucomatous visual field defects. Acta Ophthalmol (Copenh) 1983;61:728-730.Article PubMed
25. Lee DJ, Gómez-Marín O, Lam BL, Zheng DD. Glaucoma and survival: the national health interview survey 1986-1994. Ophthalmology 2003;110:1476-1483.Article PubMed
26. Lee AJ, Wang JJ, Kifley A, Mitchell P. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology 2006;113:1069-1076.Article PubMed
27. Grødum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol 2004;242:397-401.Article PubMed PDF
28. Sun J, Zhou X, Kang Y, Yan L, Sun X, Sui H, et al. Prevalence and risk factors for primary open-angle glaucoma in a rural northeast China population: a population-based survey in Bin County, Harbin. Eye (Lond) 2012;26:283-291.Article PubMed PMC PDF
29. Song W, Shan L, Cheng F, Fan P, Zhang L, Qu W, et al. Prevalence of glaucoma in a rural northern china adult population: a population-based survey in Kailu County, Inner Mongolia. Ophthalmology 2011;118:1982-1988.Article PubMed
30. Borger PH, van Leeuwen R, Hulsman CA, Wolfs RC, van der Kuip DA, Hofman A, et al. Is there a direct association between age-related eye diseases and mortality? The Rotterdam Study. Ophthalmology 2003;110:1292-1296.Article PubMed
31. Unterlauft JD, Böhm MR. Role of the aging visual system in glaucoma. Ophthalmologe 2017;114:108-113 (German).Article PubMed PDF
32. Lee SY, Lee H, Lee JS, Han SA, Kim YJ, Kim JY, et al. Association between glaucoma surgery and all-cause and cause-specific mortality among elderly patients with glaucoma: a nationwide population-based cohort study. Sci Rep 2021;11:17055.Article PubMed PMC PDF
33. Stein JD, Newman-Casey PA, Niziol LM, Gillespie BW, Lichter PR, Musch DC. Association between the use of glaucoma medications and mortality. Arch Ophthalmol 2010;128:235-240.Article PubMed
34. Wu SY, Nemesure B, Hennis A, Schachat AP, Hyman L, Leske MC, et al. Open-angle glaucoma and mortality: the Barbados Eye Studies. Arch Ophthalmol 2008;126:365-370.Article PubMed
35. Stewart WC, Osterman J. Serum lipid physiology and the influence of glaucoma medications. Surv Ophthalmol 1998;43:233-244.Article PubMed
36. French DD, Margo CE. Glaucoma medications and mortality: a retrospective cohort study. Ann Epidemiol 2010;20:917-923.Article PubMed
37. Müskens RP, Wolfs RC, Witteman JC, Hofman A, de Jong PT, Stricker BH, et al. Topical beta-blockers and mortality. Ophthalmology 2008;115:2037-2043.Article PubMed
38. Nucci C, Martucci A, Cesareo M, Garaci F, Morrone LA, Russo R, et al. Links among glaucoma, neurodegenerative, and vascular diseases of the central nervous system. Prog Brain Res 2015;221:49-65.Article PubMed
39. Rim TH, Lee SY, Bae HW, Kim SS, Kim CY. Increased stroke risk among patients with open-angle glaucoma: a 10-year follow-up cohort study. Br J Ophthalmol 2018;102:338-343.Article PubMed
40. Su CW, Chang YC, Lin CL, Chen HY. Association of neovascular glaucoma with risk of stroke: a population-based cohort study. J Ophthalmol 2017;2017:1851568.Article PubMed PMC PDF
41. Ho JD, Hu CC, Lin HC. Open-angle glaucoma and the risk of stroke development: a 5-year population-based follow-up study. Stroke 2009;40:2685-2690.Article PubMed
42. Lai SW, Lin CL, Liao KF. Glaucoma may be a non-memory manifestation of alzheimer’s disease in older people. Int Psychogeriatr 2017;1-7.Article
43. Sen S, Saxena R, Tripathi M, Vibha D, Dhiman R. Neurodegeneration in alzheimer’s disease and glaucoma: overlaps and missing links. Eye (Lond) 2020;34:1546-1553.Article PubMed PMC PDF
44. Wostyn P, Van Dam D, De Deyn PP. Alzheimer’s disease and glaucoma: look-alike neurodegenerative diseases. Alzheimers Dement 2019;15:600-601.Article PubMed PDF
45. MacAskill MR, Anderson TJ. Eye movements in neurodegenerative diseases. Curr Opin Neurol 2016;29:61-68.Article PubMed
46. Lin IC, Wang YH, Wang TJ, Wang IJ, Shen YD, Chi NF, et al. Glaucoma, alzheimer’s disease, and parkinson’s disease: an 8-year population-based follow-up study. PLoS One 2014;9:e108938.Article PubMed PMC
47. Lai SW, Lin CL, Liao KF. Glaucoma correlates with increased risk of Parkinson’s disease in the elderly: a national-based cohort study in Taiwan. Curr Med Res Opin 2017;33:1511-1516.Article PubMed
48. Sun J, Li T, Zhao X, Lu B, Chen J, Liu W, et al. Prevalence and risk factors of glaucoma among Chinese people from the China Health and Retirement Longitudinal Study. J Glaucoma 2022;31:789-795.Article PubMed
49. Shang X, Wu G, Wang W, Zhu Z, Zhang X, Huang Y, et al. Associations of vision impairment and eye diseases with frailty in community-dwelling older adults: a nationwide longitudinal study in China. Br J Ophthalmol; 2022. doi: http://dx.doi.org/10.1136/bjo-2022-322048.